About Natera
Natera is a global leader in cell-free DNA (cfDNA) testing and molecular diagnostics, serving patients and clinicians across oncology, women's health, organ health, and rare disease. The company's mission is to advance molecular diagnostics with integrity and scientific rigor, supporting the integration of test information into healthcare decision-making to enable more personalized care. Natera's technology platform measures fetal, tumor, or donor cfDNA at the molecular level through noninvasive testing. In oncology, products include Signatera™ for residual disease monitoring (MRD), Latitude™ for tissue-free MRD, Altera™ for tumor genomic profiling, and Empower™ for hereditary cancer screening. In organ health, Prospera™ tests assess kidney, heart, and lung transplant rejection, while Renasight™ provides kidney gene panel testing. Women's health offerings include Horizon™ carrier screening, Panorama™ noninvasive prenatal testing (NIPT), Vistara™ single-gene NIPT, and Anora™ miscarriage testing. The rare disease portfolio features Zenith™ genomic testing. Natera's tests are clinically validated in over 400 peer-reviewed publications with over 3 million patients studied. The company has participated in major prospective studies including CIRCULATE (oncology), SMART (women's health), and Trifecta (organ health). With over 16 million tests processed in CAP/CLIA-certified laboratories and more than 150 medical professionals on staff, Natera delivers high-quality molecular diagnostic results that help clinicians make more informed treatment decisions and enable earlier, more targeted interventions.
Mission & Story
Mission
Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making.
Clinical Focus
Medical conditions and clinical areas addressed by Natera.
Who It Serves
Milestones & Awards
Recent Milestones
Signatera™ received regulatory approval in Japan for colorectal cancer (June 2024), strategic partnerships with Aveta Biomics and Eledon announced (June 2026), bladder cancer guideline update includes Signatera™-guided care, over 16 million tests processed
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.